RxDoctor Payments Data

Mary Wegner, MD

Psychiatry · Jonesboro, ARNPI 1013983071

Payments from drug & device makers

$1,317in general payments, 2019–2025

Across 76 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$320
  • Johnson & Johnson$284
  • AbbVie$283
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$127
  • Eisai Inc.$125
  • Alkermes, Inc.$113
  • plus $64 from 2 others

What the payments were for

  • Food & beverage$1,22393%
  • Education$947%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,317 in reported general payments places this provider in the 70th percentile of 235 psychiatry providers in Arkansas.

See all psychiatry providers in Arkansas

Medicare billing

Part B allowed, 2024
$24,723
Medicare patients
52
Services billed
122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate84$245,870
VraylarCariprazine Hcl57$81,227
CaplytaLumateperone Tosylate19$35,552
Lurasidone Hcl50$14,421
Paliperidone ErPaliperidone36$6,491
Desvenlafaxine Succinate ErDesvenlafaxine Succinate58$4,313
Fluphenazine Decanoate28$2,401
Mirtazapine98$1,938
Olanzapine75$1,806
Clozapine17$1,530
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine32$1,336
Duloxetine Hcl118$1,306
Quetiapine Fumarate82$1,193
Venlafaxine Hcl ErVenlafaxine Hcl63$949
Fluphenazine Hcl12$873

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$284$245,87084 claims
AbbVieVraylar$283$81,22757 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$127$35,55219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 235 psychiatry providers in Arkansas.

Other psychiatry in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →